JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL DATA OF KRAS G12C INHIBITOR JAB-21822 WILL BE PRESENTED AT THE 2022 ASCO ANNUAL MEETING

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD., Ltd. (the "**Company**" or "**Jacobio**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the "**Board**") is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) ("**2022 ASCO Annual Meeting**") from June 3, 2022 to June 7, 2022.

Abstract of the study was published on the ASCO's website today.

About the Abstract

Title	A phase I/II study of the first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors
Format	Poster Presentation
Abstract Number	3089
Time	Sunday, June 5, 2022 8:00 AM-11:00 AM (CDT) Sunday, June 5, 2022 9:00 PM- Monday, June 6, 2022 12:00 AM (Beijing Time)
Track	Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

As of January 28, 2022, 53 patients with a median age of 62 years (39-79) were enrolled in 5 different dose levels: 200mg QD, 400mg QD, 800mg QD, 400mg BID and 400mg TID. A total of 33 patients (22 non-small cell lung cancer, 9 colorectal cancer and 2 pancreatic cancer) had at least 1 post-baseline tumor assessment.

- Patients with non-small cell lung cancer (400mg QD and 800mg QD), the overall response rate (ORR) and disease control rate (DCR) were 70% (7/10) and 100% (10/10), respectively.

- No dosing-limiting toxicities were observed. Only Grade 1 and 2 treatment-related adverse events were observed in the QD cohorts.

JAB-21822 was well tolerated with impressive preliminary efficacy in patients with heavily treated solid tumors harboring KRAS G12C mutation. The clinical trial is still ongoing and the above data is as of January 28, 2022.

Updated data will be presented in a poster session at the 2022 ASCO Annual Meeting, please visit www.asco.org for more information.

About JAB-21822

JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors, including monotherapy for STK11 co-mutated non-small cell lung cancer in the front-line setting; combination therapy with SHP2 inhibitor, anti-PD-1 monoclonal antibody and Cetuximab.

About the Company

The Company is committed to providing more products and solutions to people's health. Our mission is to provide compelling innovations for creating a pipeline of life-changing medicines. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. The company's R&D centers are located in Beijing and Shanghai of China, and Boston of the United States, with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, KRAS G12C Inhibitor JAB-21822 and combination therapies of JAB-21822 successfully. Please visit www.jacobiopharma.com for more information.

On behalf of the Board of Directors
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, May 27, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Ge WU and Dr. Daqing CAI as independent non-executive Directors.